News

October 20, 2024

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more

News

September 19, 2024

Positive Results from Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2024 in Late-Breaking Session

Stockholm, Sweden, September 19, 2024. Affibody today announced that the positive results from a Phase 3 trial of izokibep in hidradenitis suppurativa will be presented at the 2024 European...

Read more

News

June 5, 2024

Positive 16-week Data From Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis Presented at EULAR 2024 Late Breaking Session

Stockholm, Sweden, June 5, 2024. Affibody today announced that positive 16-week data from a global Phase 2b/3 trial of izokibep in psoriatic arthritis (PsA) will be presented at the...

Read more

News

April 18, 2024

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Thursday...

Read more

News

March 19, 2024

Change in Affibody’s Nomination Committee for the 2024 Annual General Meeting

Stockholm, Sweden, March 19, 2024. Affibody Medical AB (publ) today announced a change of the composition of the Nomination Committee for the 2024 Annual General Meeting (AGM) to be...

Read more

News

November 13, 2023

Presentation at Amercian College of Rheumatology (ACR) Convergence 2023 of positive izokibep long-term data from Phase 2 study

Solna, Sweden, November 13, 2023. Affibody today announced that positive long-term data from a Phase 2 trial of izokibep in Psoriatic Arthritis (PsA) will be presented at the ACR...

Read more

News

November 8, 2023

Affibody’s Nomination Committee for the 2024 Annual General Meeting

Stockholm, Sweden, November 8, 2023. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2024 Annual General Meeting (AGM) to be held on May...

Read more

News

September 12, 2023

First Long-Term Clinical Study of Izokibep Published

Solna, Sweden, September 12, 2023. The first publication outlining phase 2 efficacy and safety results from a long-term study of izokibep, a small biological IL-17A inhibitor, is now available...

Read more

News

September 3, 2023

Affibody’s Partner Rallybio Presents Phase 1 Results at the 29th International Complement Workshop (ICW 2023)

Solna, Sweden, September 3, 2023. Affibody’s partner Rallybio Corporation (Nasdaq: RLYB) today presented results from the Phase 1 first-in-human clinical study of RLYB116 as a poster at ICW 2023...

Read more